Leukemia - Table of Contents alert Volume 32 Issue 4

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 32, Issue 4 (April 2018) In this issue Original Articles Letters to the Editor Correspondence Corrigendum Also new AOP   Original Articles Acute myeloid leukemia Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia S Fujita, D Honma, N Adachi, K Araki, E Takamatsu et al. Leukemia 2017 32 :855 - 864; September 27, 2017; 10.1038/leu.2017.300   Abstract | Full Text A vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target F Yan, N Shen, J X Pang, N Zhao, Y W Zhang et al. Leukemia 2017 32 :865 - 873; October 10, 2017; 10.1038/leu.2017.307   Abstract | Full Text Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia L Lhermitte, E Mejstrikova, A J van der Sluijs-Gelling, G E Grigore, L Sedek et al. Leukemia 2017 32 :874 - 881; November 01, 2017; 10.1038/leu.2017.313   Abstract | Full Text Targeting acute myeloid leukemia by drug-induced c-MYB degradation V Walf-Vorderwülbecke, K Pearce, T Brooks, M Hubank, M M van den Heuvel-Eibrink et al. Leukemia 2017 32 :882 - 889; November 01, 2017; 10.1038/leu.2017.317   Abstract | Full Text SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia J Bu, A Chen, X Yan, F He, Y Dong et al. Leukemia 2017 32 :890 - 899; November 29, 2017; 10.1038/leu.2017.339   Abstract | Full Text AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo A Unnikrishnan, A N Q Vo, R Pickford, M J Raftery, A C Nunez et al. Leukemia 2017 32 :900 - 910; November 29, 2017; 10.1038/leu.2017.340   Abstract | Full Text The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia A G Sanarico, C Ronchini, A Croce, E M Memmi, U A Cammarata et al. Leukemia 2017 32 :911 - 919; December 06, 2017; 10.1038/leu.2017.342   Abstract | Full Text Molecular targets for therapy Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy V K Patel, B Lamothe, M L Ayres, J Gay, J P Cheung et al. Leukemia 2017 32 :920 - 930; November 03, 2017; 10.1038/leu.2017.321   Abstract | Full Text Acute lymphoblastic leukemia RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia I S Jerchel, A Q Hoogkamer, I M Ariës, E M P Steeghs, J M Boer et al. Leukemia 2017 32 :931 - 940; October 03, 2017; 10.1038/leu.2017.303   Abstract | Full Text Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system S Bornschein, S Demeyer, R Stirparo, O Gielen, C Vicente et al. Leukemia 2017 32 :941 - 951; November 20, 2017; 10.1038/leu.2017.328   Abstract | Full Text Chronic myelogenous leukemia Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine R J Molenaar, C Pleyer, T Radivoyevitch, S Sidana, A Godley et al. Leukemia 2017 32 :952 - 959; November 06, 2017; 10.1038/leu.2017.323   Abstract | Full Text Chronic lymphocytic leukemia Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway K Kondo, H Shaim, P A Thompson, J A Burger, M Keating et al. Leukemia 2017 32 :960 - 970; October 03, 2017; 10.1038/leu.2017.304   Abstract | Full Text Multiple myeloma, gammopathies Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials P Arana, B Paiva, M-T Cedena, N Puig, L Cordon et al. Leukemia 2017 32 :971 - 978; November 03, 2017; 10.1038/leu.2017.320   Abstract | Full Text Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma S Bringhen, M D'Agostino, L De Paoli, V Montefusco, A M Liberati et al. Leukemia 2017 32 :979 - 985; November 16, 2017; 10.1038/leu.2017.327   Abstract | Full Text Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time S K Kumar, A Dispenzieri, R Fraser, F Mingwei, G Akpek et al. Leukemia 2017 32 :986 - 995; November 16, 2017; 10.1038/leu.2017.331   Abstract | Full Text Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma A Gullà, T Hideshima, G Bianchi, M Fulciniti, M Kemal Samur et al. Leukemia 2017 32 :996 - 1002; November 21, 2017; 10.1038/leu.2017.334   Abstract | Full Text MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells C Botta, M Cucè, M R Pitari, D Caracciolo, A Gullà et al. Leukemia 2017 32 :1003 - 1015; November 21, 2017; 10.1038/leu.2017.336   Abstract | Full Text Chronic myeloproliferative neoplasms Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells B Peter, S Bibi, G Eisenwort, B Wingelhofer, D Berger et al. Leukemia 2017 32 :1016 - 1022; November 29, 2017; 10.1038/leu.2017.338   Abstract | Full Text Stem cell biology Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS Y Mei, B Zhao, A A Basiorka, J Yang, L Cao et al. Leukemia 2017 32 :1023 - 1033; November 16, 2017; 10.1038/leu.2017.326   Abstract | Full Text Letters to the Editor Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis A Pardanani, J Gotlib, A W Roberts, M Wadleigh, S Sirhan et al. Leukemia 2017 32 :1034 - 1037; November 16, 2017; 10.1038/leu.2017.330   Abstract | Full Text Towards ‘off-the-shelf’ genetically modified T cells: prolonging functional engraftment in mice by CD8 veto T cells N Or-Geva, R Gidron-Budovsky, L Radomir, Y Edelstein, A K Singh et al. Leukemia 2017 32 :1038 - 1040; November 20, 2017; 10.1038/leu.2017.332   Abstract | Full Text Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity S Marsilio, H Khiabanian, G Fabbri, S Vergani, C Scuoppo et al. Leukemia 2017 32 :1040 - 1043; December 05, 2017; 10.1038/leu.2017.343   Abstract | Full Text Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines F Maura, M Petljak, M Lionetti, I Cifola, W Liang et al. Leukemia 2017 32 :1043 - 1047; December 06, 2017; 10.1038/leu.2017.345   Abstract | Full Text CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC I Tirado-Gonzalez, E Czlonka, A Nevmerzhitskaya, D Soetopo, E Bergonzani et al. Leukemia 2017 32 :1048 - 1051; December 06, 2017; 10.1038/leu.2017.346   Abstract | Full Text Correspondence The role of bone marrow morphology in the diagnosis of relapsed acute myeloid leukemia B Said, S Gilles, D Weisdorf & A Rashidi Leukemia 2017 32 :1052 - 1052; October 31, 2017; 10.1038/leu.2017.308   Abstract | Full Text Corrigendum Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML C Schütz, S Inselmann, S Saussele, C T Dietz, M C Müller et al. Leukemia 2018 32 :1053 - 1053; January 30, 2018; 10.1038/leu.2017.348   Abstract | Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.